News
George Thomas and Antonio Gentilella publish a comment on Nature
The journal Nature has published in its first issue of May, a commentary by the director of the IDIBELL’s Metabolism and Cancer research group, George Thomas, and the researcher of the same group Antonio Gentilella. Los investigadores hablan sobre dos estudios publicados en el mismo número de la revista, sobre la proteína quinasa mTOR, un […]
Combination of two drugs reverses liver tumours
The combination of two inhibitors of protein mTOR stops the growth of primary liver cancer and destroys tumour cells, according to a study by researchers of the Group of Metabolism and Cancer at Bellvitge Biomedical Research Institute (IDIBELL). The study results are been published on the online edition of the journal Science Translational Medicine. Primary […]
ICO receives the highest international distinction for his fight against smoking
The Catalan Institute of Oncology (ICO) L’Hospitalet has been recognized with the ‘gold standard’ of the Global Network for Tobacco Free Health Care Services (ENSH). This is the highest international distinction given to those health centers that have demonstrated significant progress in tobacco control policies and represent an example for other organizations in the fight […]
The University Hospital of Bellvitge receives one of the Profesor Barea Awards 2012 on health management
On 19 April, the Signo Foundation presented the Profesor Barea Awards 2012, an initiative to highlight and recognize the work of public and private institutions to improve health management and development of new initiatives that seek to optimize the healthcare services. In the category “Healthcare facilities and service companies: Global Management” has been awarded the […]
Núria Malats: ”the challenge of epidemiology is to analyze all information relating to a disease”
The integration of different levels of information associated with a disease, such as issues related to environmental exposure, epigenetics, genetics, genomics, metabolomics, transcriptomics and proteomics, requires the development of innovative designs and new methodological tools. The head of the research group on Molecular Epidemiology and Genetics at the Spanish National Cancer Research Centre (CNIO), Núria […]
IDIBELL researches to cure cystic fibrosis
On Wednesday April 25 we commemorate the national day of cystic fibrosis, one of the most common serious genetic diseases, affecting one in five thousand births. The Human Molecular Genetics research group at IDIBELL searches new treatments for cystic fibrosis, both from a functional approach and from the development of gene therapies. The research carried […]
Jesús San Miguel: ”The goal is to demonstrate that early treatment against pre-myeloma improves survival”
One of the foremost experts in the field of multiple myeloma, Jesus San Miguel, explained in IDIBELL seminar series on 13 April, the approach to this disease that makes his research group at the University Hospital of Salamanca. The researcher explained that one objective is to understand the pathogenesis of the disease: “We want to […]
Manel Esteller, chosen Elect Academic of the Royal Academy of Medicine of Catalonia
The researcher Manel Esteller, director of the Cancer and Epigenetics Biology Program at the Bellvitge Biomedical Research Institute (IDIBELL), Professor of Genetics at the University of Barcelona and ICREA Research Professor has chosen Academic Elect of the Royal Academy of Medicine of Catalonia (RAMC). Esteller will occupy the space left by Moises Broggi, Creu de […]
Oriol Casanovas reviews limitations of antiangiogenic therapies at Nature
IDIBELL researcher Oriol Casanovas has published in the latest issue of Nature an article titled “Limitations of therapies exposed” where he highlights the need to know the limitations of antiangiogenic therapies to open doors to new combinations and therapeutic approaches that involve greater benefits for patients. Specifically, Casanovas comments two recent publications which expose the […]